AstraZeneca is a global, science-led, patient-centred biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines for some of the world’s most serious disease. But we’re more than one of the world’s leading pharmaceutical companies. At AstraZeneca, we 're dedicated to being a Great Place to Work where you are empowered to push the boundaries of science and fuel your entrepreneurial spirit. There’s no better place to make a difference to medicine, patients and society.
About the Postdoc Programme:
AstraZeneca’s Postdoc Programme is for self-motivated individuals looking to tackle exciting, high impact projects in a collaborative, engaging and innovative environment. You'll work with peers and professionals from a diverse group of backgrounds, and a world class academic mentor specifically aligned to your project. We'll help you develop valuable networks which support your research and future career development!
Our vibrant, multi-disciplinary scientific teams empower and support our Postdocs, and we encourage them to share their research at conferences, publish papers, achieve their goals and make a difference to our patients. You'll learn from industry leaders working on innovative research across our organization.
Are you ready to explore this exciting next step in your research career? Apply today!
About the Opportunity
At AstraZeneca, we turn ideas into life changing medicines. Working here means being entrepreneurial, thinking big and working together to make the impossible a reality. We’re passionate about the potential of science to address the unmet needs of patients around the world. We commit to those areas where we believe we can really change the course of medicine and bring big new ideas to life.
AstraZeneca’s vision in Oncology is to push the boundaries of science to change the practice of medicine, transform the lives of patients living with cancer, and to ultimately eliminate cancer as a cause of death.
Working in this laboratory-based position within the Immuno-Oncology Research group you will develop, design, conduct and analyse experiments to assess the role of ICB on T regulatory cell phenotype and function within the tumour microenvironment. You will also review emerging literature and internal data to help in identifying new potential targets and contribute to target validation activities.
Immune checkpoint blockade (ICB) is the standard of care for a broad range of tumour types. To date regulatory approvals centre on two key co-inhibitory pathways, PD-1 and CTLA-4 which negatively regulate T cell receptor and CD28 co-receptor signalling.
The consequences of CTLA-4 inhibition on Treg remain unclear. Previous studies have demonstrated that inhibition of CTLA-4 is required on both effector and Treg compartments for maximal anti-tumour activity. In contrast, CTLA-4 blockade has also been shown to induce expansion of the Treg compartment in a dose-dependent fashion. This project aims to clarify the consequences of CTLA-4 inhibition on Treg and how this inhibition, when combined with PD-1 blockade, influences Treg phenotype and function.
You will be embedded in a well-integrated, collaborative team of bench in vitro and in vivo scientist. You’ll learn data science skills, expand your single cell analysis capabilities, and could develop the project further collaborating with the different groups within AZ.
Our ambition is for you to publish this research in high impact journals, and share your findings via conference presentations at both national and international level.
|Salary:||Competitive + Excellent Benefits|
|Placed On:||16th November 2021|
|Closes:||12th December 2021|
Type / Role: